Search

Your search keyword '"Stengel, Rainer"' showing total 9 results
Start Over Author "Stengel, Rainer"
9 results on '"Stengel, Rainer"'

3. Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide

Author

Ryder, Robert E.J., primary, Laubner, Katharina, additional, Benes, Marek, additional, Haluzik, Martin, additional, Munro, Lynne, additional, Frydenberg, Harry, additional, Teare, Julian P., additional, Ruban, Aruchana, additional, Fishman, Sigal, additional, Santo, Erwin, additional, Stengel, Rainer, additional, De Jonge, Charlotte, additional, Greve, Jan W., additional, Cohen, Ricardo V., additional, Aboud, Cristina M., additional, Holtmann, Gerald J., additional, Rich, Graeme, additional, McMaster, Jess J., additional, Battelino, Tadej, additional, Kotnik, Primoz, additional, Byrne, James P., additional, Mason, John C., additional, Bessell, Justin, additional, Bascomb, Jeanine, additional, Kow, Lillian, additional, Collins, Janes, additional, Chisholm, Jacob, additional, Pferschy, Peter N., additional, Sourij, Harald, additional, Cull, Melissa L., additional, Wyres, Melanie C., additional, Drummond, Russell, additional, McGowan, Barbara, additional, Amiel, Stephanie A., additional, Yadagiri, Mahi, additional, Sen Gupta, Piya, additional, Aberle, Jens, additional, and Seufert, Jochen, additional

Published
2023
Full Text
View/download PDF

4. 1415-P: Risk–Benefit Data from the Worldwide EndoBarrier (EB) Registry

Author

RYDER, ROBERT E.J., primary, TEARE, JULIAN P., additional, RUBAN, ARUCHUNA, additional, HALUZIK, MARTIN, additional, MUNRO, LYNNE, additional, FRYDENBERG, HARRY, additional, MCMASTER, JESSICA J., additional, FISHMAN, SIGAL, additional, STENGEL, RAINER, additional, COHEN, RICARDO V., additional, ABOUD, CRISTINA M., additional, BYRNE, JAMES P., additional, HOLTMANN, GERALD J., additional, DE JONGE, CHARLOTTE, additional, GREVE, JAN WILLEM, additional, MASON, JOHN C., additional, BESSELL, JUSTIN, additional, KOW, LILIAN, additional, SOURIJ, HARALD, additional, PFERSCHY, PETER N., additional, CULL, MELISSA L., additional, WYRES, MELANIE C., additional, DRUMMOND, RUSSELL, additional, MCGOWAN, BARBARA, additional, AMIEL, STEPHANIE A., additional, YADAGIRI, MAHENDER, additional, GUPTA, PIYA SEN, additional, LAUBNER, KATHARINA, additional, and SEUFERT, JOCHEN, additional

Published
2022
Full Text
View/download PDF

6. Effectiveness of Emollients in the Prevention of Atopic Dermatitis in Infants: A Meta-Analysis.

Author

Xu, Di, Stengel, Rainer, and Sun, Pengfei

Subjects
ATOPIC dermatitis, INFANTS, RANDOMIZED controlled trials, PUBLICATION bias
Abstract

Background: Atopic dermatitis (AD) is a chronic skin disease characterized by dry skin, severe itching, inflammation and impaired quality of life. Moisturizing is an integral part of treatment for AD, but its potential for prevention of AD is unclear. Objective: To evaluate whether the early use of emollients in infancy can prevent later development of AD. Methods: We searched Medline, Embase, Web of Science, PubMed, Cochrane Library and other databases to collect randomized controlled trials on early use of emollients in infants for a meta-analysis. Results: Nine articles were included. The OR value for incidence rate was 0.7 (95% CI: 0.48–1.01). No significant publication bias was found by Egger's test. The sensitivity analysis indicated that the final conclusion was reliable. Conclusions: We found that the difference in incidence rate of AD between the experimental and control groups was not statistically significant. However, due to different methods of using emollients, different follow-up times and different sample sizes included in this meta-analysis, a definitive conclusion could not be reached in this study. In the future, it is still necessary to carry out randomized controlled, multicenter, large-sample trials with an excellent study design and high methodological quality on early application of emollients in high-risk infants to prevent AD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

8. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study

Author

Laubner, Katharina, primary, Riedel, Nina, additional, Fink, Katharina, additional, Holl, Reinhard W., additional, Welp, Reinhard, additional, Kempe, Hans-Peter, additional, Lautenbach, Anne, additional, Schlensak, Matthias, additional, Stengel, Rainer, additional, Eberl, Thomas, additional, Dederichs, Frank, additional, Schwacha, Henning, additional, Seufert, Jochen, additional, and Aberle, Jens, additional

Published
2018
Full Text
View/download PDF

9. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus : a case control study

Author

Laubner, Katharina, Riedel, Nina, Fink, Katharina, Holl, Reinhard, Welp, Reinhard, Kempe, Hans-Peter, Lautenbach, Anne, Schlensak, Matthias, Stengel, Rainer, Eberl, Thomas, Dederichs, Frank, Schwacha, Henning, Seufert, Jochen, and Aberle, Jens

Subjects
Diabetes mellitus, Type 2, Fettsucht, Glycaemic control, Weight control, Diabetes mellitus Typ 2, Obesity, Therapy, Therapie, DDC 610 / Medicine & health, 3. Good health
Abstract

Aims: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device mimicking surgical duodenal-jejunal bypass, and is indicated for the treatment of obesity-associated type 2 diabetes mellitus. This analysis was conducted to evaluate the efficacy and safety of the DJBL in comparison to lifestyle changes and antidiabetic drugs. Materials and methods: To determine the efficacy and long-term safety of the DJBL, data concerning 235 obese patients with type 2 diabetes mellitus from the German DJBL registry were analysed. For comparison with standard treatment, propensity-score-matching with patients from the German DPV registry, including the matching parameters sex, age, diabetes duration, baseline BMI and baseline HbA1c, was applied. The final matched cohort consisted of 111 patients in the DJBL group and 222 matched control DPV patients. Results: Mean treatment time with the DJBL was 47.5 �� 12.2 weeks, mean BMI reduction was 5.0 kg/m2 (P < .001) and mean HbA1c reduction was 1.3% (11.9 mmol/mol) (P < .001). Reduction of antidiabetic medications and improvements in other metabolic and cardiovascular risk parameters was observed. In comparison to the matched control group, mean reductions in HbA1c (-1.37% vs -0.51% [12.6 vs 3.2 mmol/mol]; P < .0001) and BMI (-3.02 kg/m2 vs -0.39 kg/m2 ; P < .0001) were significantly higher. Total cholesterol, LDL cholesterol and blood pressure were also significantly better. Conclusion: This study provides the largest, so far, hypothesis-generating evidence for a putative positive risk/benefit ratio for treatment of obese patients with type 2 diabetes mellitus with the DJBL as an alternative treatment option for this patient population. �� 2018 John Wiley & Sons Ltd., acceptedVersion

Catalog

Books, media, physical & digital resources
See catalog results